Results 91 to 100 of about 258,881 (309)

Supplementary Figure 1 from Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8⁺ T Cells [PDF]

, 2023
Jérémy Goc, Claire Germain, Thi Kim Duy Vo-Bourgais, Audrey Lupo, Christophe Klein, Samantha Knockaert, Luc de Chaisemartin, Hanane Ouakrim, Étienne Becht, Marco Alifano, Pierre Validire, Romain Remark, Scott A. Hammond, Isabelle Cremer, Diane Damotte, Wolf H. Fridman, Catherine Sautès‐Fridman, Marie‐Caroline Dieu‐Nosjean   +17 more
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Prognostic impact of tertiary lymphoid structures in breast cancer prognosis: a systematic review and meta-analysis [PDF]

, 2021
Nana Zhang, Fengjin Qu, Hao Liu, Zhujun Li, Yuchi Zhang, Xuan Han, Ziyu Zhu, Yi Lv   +7 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Simultaneous prediction of RNA secondary structure and helix coaxial stacking

BMC Genomics, 2012
Background RNA secondary structure plays a scaffolding role for RNA tertiary conformation. Accurate secondary structure prediction can not only identify double-stranded helices and single stranded-loops but also help provide information for potential ...
Shareghi Pooya, Wang Yingfeng, Malmberg Russell, Cai Liming   +3 more
doaj   +1 more source

Modeling of tertiary and quaternary protein structures by homology [PDF]

, 2012
Florian Kiefer
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Improving AlphaFold2-based protein tertiary structure prediction with MULTICOM in CASP15. [PDF]

Commun Chem, 2023
Liu J, Guo Z, Wu T, Roy RS, Chen C, Cheng J.   +5 more
europepmc   +1 more source

The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures [PDF]

, 2020
Ling‐Ling Chen, Teniola Oke, Nicholas Siegel, Gady Cojocaru, Ada Tam, Richard L. Blosser, Jessica Swailes, John A. Ligon, Andriana Lebid, Carol D. Morris, Adam S. Levin, Daniel S. Rhee, Fabian M. Johnston, Jonathan B. Greer, Christian F. Meyer, Brian H. Ladle, Elizabeth D. Thompson, Elizabeth A. Montgomery, Woonyoung Choi, David J. McConkey, Robert A. Anders, Drew M. Pardoll, Nicolás J. Llosa   +22 more
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source